Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
Document Type
- Journal article (13)
Language
- English (13)
Keywords
- prostate cancer (5)
- RCC (2)
- biomarker (2)
- biomarkers (2)
- high-risk prostate cancer (2)
- prognosis (2)
- Biomarker (1)
- Cancer Cell (1)
- CpG island hypermethylation (1)
- GSTP1 (1)
- Kidney cancer (1)
- LASP1 (1)
- LNCaP (1)
- MircoRNA (1)
- PSA (1)
- Profiling (1)
- Prognosis (1)
- Renal cell carcinoma (1)
- SOAT1 (1)
- Sunitinib (1)
- Tumour markers (1)
- Tyrosine kinase inhibition (1)
- adjuvant hormonal treatment (1)
- angiogenesis (1)
- cholesterol metabolism (1)
- diagnosis (1)
- forecasting (1)
- gene (1)
- gene expression (1)
- gene targeting (1)
- high-risk Prostate Cancer (1)
- kidney cancer (1)
- kidneys (1)
- luciferase (1)
- lymph node dissection (1)
- metastasis (1)
- miR (1)
- miR-126 (1)
- miR-205 (1)
- miR-21 (1)
- miR-221-5p (1)
- miRNA (1)
- microRNA (1)
- microRNA-221 (1)
- microarrays (1)
- migration (1)
- mir-203 (1)
- oncogenes (1)
- positive lymph node (1)
- proliferation (1)
- promoter methylation (1)
- radical prostatectomy (1)
- receptor beta (1)
- recurrence (1)
- regression analysis (1)
- renal cancer (1)
- renal cell carcinoma (1)
- reveals (1)
- risk stratification (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical oncology (1)
- tumor suppressor miRNA (1)
- venous infiltration (1)
Institute
- Urologische Klinik und Poliklinik (13)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Pathologisches Institut (3)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Medizinische Klinik und Poliklinik I (1)
Sonstige beteiligte Institutionen
Downregulation of miR-221-3p expression in prostate cancer (PCa) predicted overall and cancer-specific survival of high-risk PCa patients. Apart from PCa, miR-221-3p expression levels predicted a response to tyrosine kinase inhibitors (TKI) in clear cell renal cell carcinoma (ccRCC) patients. Since this role of miR-221-3p was explained with a specific targeting of VEGFR2, we examined whether miR-221-3p regulated VEGFR2 in PCa. First, we confirmed VEGFR2/KDR as a target gene of miR-221-3p in PCa cells by applying Luciferase reporter assays and Western blotting experiments. Although VEGFR2 was mainly downregulated in the PCa cohort of the TCGA (The Cancer Genome Atlas) database, VEGFR2 was upregulated in our high-risk PCa cohort (n = 142) and predicted clinical progression. In vitro miR-221-3p acted as an escape mechanism from TKI in PC3 cells, as displayed by proliferation and apoptosis assays. Moreover, we confirmed that Sunitinib induced an interferon-related gene signature in PC3 cells by analyzing external microarray data and by demonstrating a significant upregulation of miR-221-3p/miR-222-3p after Sunitinib exposure. Our findings bear a clinical perspective for high-risk PCa patients with low miR-221-3p levels since this could predict a favorable TKI response. Apart from this therapeutic niche, we identified a partially oncogenic function of miR-221-3p as an escape mechanism from VEGFR2 inhibition.
Background
Prostate cancer (PCa) is the most frequent cancer in men. The prognosis of PCa is heterogeneous with many clinically indolent tumors and rare highly aggressive cases. Reliable tissue markers of prognosis are lacking. Active cholesteryl ester synthesis has been associated with prostate cancer aggressiveness. Sterol-O-Acyl transferases (SOAT) 1 and 2 catalyze cholesterol esterification in humans.
Objective
To investigate the value of SOAT1 and SOAT2 tissue expression as prognostic markers in high risk PCa.
Patients and Methods
Formalin-fixed paraffin-embedded tissue samples from 305 high risk PCa cases treated with radical prostatectomy were analyzed for SOAT1 and SOAT2 protein expression by semi-quantitative immunohistochemistry. The Kaplan-Meier method and Cox proportional hazards modeling were used to compare outcome.
Main Outcome Measure
Biochemical recurrence (BCR) free survival.
Results
SOAT1 expression was high in 73 (25%) and low in 219 (75%; not evaluable: 13) tumors. SOAT2 was highly expressed in 40 (14%) and at low levels in 249 (86%) samples (not evaluable: 16). By Kaplan-Meier analysis, we found significantly shorter median BCR free survival of 93 months (95% confidence interval 23.6-123.1) in patients with high SOAT1 vs. 134 months (112.6-220.2, Log-rank p < 0.001) with low SOAT1. SOAT2 expression was not significantly associated with BCR. After adjustment for age, preoperative PSA, tumor stage, Gleason score, resection status, lymph node involvement and year of surgery, high SOAT1 but not SOAT2 expression was associated with shorter BCR free survival with a hazard ratio of 2.40 (95% CI 1.57-3.68, p < 0.001). Time to clinical recurrence and overall survival were not significantly associated with SOAT1 and SOAT2 expression CONCLUSIONS: SOAT1 expression is strongly associated with BCR free survival alone and after multivariable adjustment in high risk PCa. SOAT1 may serve as a histologic marker of prognosis and holds promise as a future treatment target.
(1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC\(^{IVC}\)) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier — containing miR-21-5p, miR-126-3p and miR-221-3p expression — which significantly predicted the cancer-specific survival (CSS) of ccRCC\(^{IVC}\) patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC\(^{IVC}\), we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan–Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan–Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC\(^{IVC}\) according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC\(^{IVC}\) cohort.